This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Pharmacy Europe     Newsletter          
HOPE LOGO

Search results for "" (5834)


 
Two phase 3 trials find bimekizumab effective in both forms of axial spondyloarthritis
A coffee intake change from low to moderate reduces total body fat in metabolic syndrome
Rucaparib offers survival advantage over usual care in metastatic prostate cancer
Aspirin use benefits reduced by statins in those without atherosclerotic disease
Poor cardiovascular risk control identified in half of men with prostate cancer
Increased NT-proBNP levels over time linked to greater risk of heart failure and death
Prior COVID-19 infection provides similar protection as two doses of mRNA vaccine
EMA refuses lagevrio marketing authorisation for treatment of COVID
Decongestant medicines under review by regulators after rare side effects
NICE rejects rimegepant for acute migraine treatment
Automated dispensing systems for the safe management of controlled drugs
Adherence to NICE criteria for biologic treatment in atopic dermatitis
Syfovre approved for geographic atrophy in advanced age-related macular degeneration
Pregnancy hypertensive disorders linked to higher future risk of cardiovascular disease
Pembrolizumab shows benefit in high-risk BCG non-responsive bladder cancer
T-VEC virotherapy and NAC improves response in triple negative breast cancer
Hemgenix first gene therapy approved in EU for haemophilia B
Tracking the anticholinergic burden score during hospital admission in acute care
Fetal alcohol spectrum disorders: An overview
Creating a fluid stewardship committee in a UK hospital
Delivering neonatal parenteral nutrition: the importance of the MDT
Darolutamide improves overall survival in metastatic hormone sensitive prostate cancer
Enhanced recovery after surgery and peri-operative pharmacy services
Medicines optimisation for the frail older person
Optimising physical health in individuals with severe mental illness and the role of pharmacy
Neoadjuvant nivolumab provides significant 5-year overall survival in lung cancer
Study reveals significant increase in hospital admissions for COPD and asthma

×